AKRO News and Press, Akero Therapeutics Inc. From 11/10/23

Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...

2023-11-09 13:01:38 ET Summary Madrigal Pharmaceuticals is more than 100% higher than a year ago, though the stock has been grinding constantly lower from it's high-water mark in late-April, sitting some 55% below that level. The company completed a $500 million stock offering to ...

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...

Akero Therapeutics Inc. (AKRO) is expected to report $-0.69 for Q3 2023

2023-10-26 01:30:02 ET Summary 89bio shows promise in NASH therapeutics, backed by robust Phase 2b trials of its drug pegozafermin. Financially stable with a significant cash runway, but a sharp YoY increase in operating expenses without a partnership to offset some costs is a con...

2023-10-20 15:00:13 ET More on the markets S&P 500 Will Likely Underperform And 5% Money Markets Are NOT The Answer Equities Climbing A Wall Of Worry (Technical Analysis) SPY: Short-Term Bounce Testing The Downtrends (Technical Analysis) Here is why you s...

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present virtually ...

2023-10-12 16:38:06 ET Shares of Akero Therapeutics (NASDAQ: AKRO) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence . The healthcare stock closed last week at $50.33, then hit a 52-week low of $14.0...

2023-10-10 15:58:09 ET More on Akero Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data Akero Therapeutics: An Assessment Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more Akero plummets after m...

2023-10-10 13:28:32 ET Summary Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Despite the setback, AKRO stock is still trading higher than it was in September 2022, before another Phase 2 study succeeded...